Morningstar's X4 Pharmaceuticals Inc Stock Analysis
Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.
X4 Pharmaceuticals Inc's Company Profile
X4 Pharmaceuticals Inc is clinical-stage biopharmaceutical company. It is focused on restoring the immune system function by developing therapeutics for the treatment of rare diseases. Its molecule therapeutics are antagonists of chemokine receptor CXCR4, which have the potential to treat a broad range of rare diseases, including primary immunodeficiencies (PIs) and cancer. Its product candidate, X4P-001, has completed a Phase 2 trial in patients with a rare genetic PI called Warts. The company is also developing X4P-002, a CXCR4 antagonist that has properties that could enable penetration of the blood-brain barrier and provide appropriate therapeutic exposures to treat brain cancers, including glioblastoma multiforme.
Boston, MA, 02134